PTPRC and neoplasm: There was a significant reduction in tumor CD45+CD11b+Ly6C+Ly6G–CX3CR1+ monocytes and spleen eosinophils (CD45+CD11b+Siglec F+) and no significant change in DCs (CD45+CD11b+CD11c+) and PMN-MDSCs (CD45+CD11b+Ly6CloLy6Ghi) (Supplemental Figure 5, A and B).